Aspire Biopharma Holdings, Inc.
ASBP
$1.76
-$0.13-6.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.90K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90K | -- | -- | -- | -- |
| Cost of Revenue | 1.10K | -- | -- | -- | -- |
| Gross Profit | 900.00 | -- | -- | -- | -- |
| SG&A Expenses | 3.07M | 2.34M | 1.98M | 1.04M | 581.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.01M | 3.08M | 2.38M | 1.18M | 619.50K |
| Operating Income | -4.01M | -3.08M | -2.38M | -1.18M | -619.50K |
| Income Before Tax | -20.51M | -18.88M | -16.99M | -1.28M | -619.50K |
| Income Tax Expenses | 0.00 | 1.00K | 1.00K | 1.00K | 1.50K |
| Earnings from Continuing Operations | -20.51 | -18.88 | -16.99 | -1.28 | -0.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.51M | -18.88M | -16.99M | -1.28M | -621.00K |
| EBIT | -4.01M | -3.08M | -2.38M | -1.18M | -619.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -20.00 | -18.82 | -17.35 | -0.86 | -0.79 |
| Normalized Basic EPS | -2.99 | -2.25 | -1.52 | -0.53 | -0.49 |
| EPS Diluted | -20.00 | -18.82 | -17.35 | -0.86 | -0.79 |
| Normalized Diluted EPS | -2.99 | -2.25 | -1.52 | -0.53 | -0.49 |
| Average Basic Shares Outstanding | 14.42M | 13.87M | 13.33M | 13.07M | 445.07M |
| Average Diluted Shares Outstanding | 14.42M | 13.87M | 13.33M | 13.07M | 445.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |